Funding Opportunities

There are many funding opportunities that support the conduct of rigorous, cutting-edge dissemination and implementation research at the National Cancer Institute (NCI) and across the National Institutes of Health (NIH). The most prominent funding opportunity is the Trans-NIH program announcement with special receipt, referral and/or review (PAR), Dissemination and Implementation Research in Health (DIRH). NCI, along with many other participating institutes and centers across NIH, issued this PAR for R01, R21, and/or R03 funding sources. Learn more about this implementation science (IS) funding opportunity and find resources for prospective IS applicants.

Funding Announcements

Trans-NIH PAR, Dissemination and Implementation Research in Health

Successful Grant Applications

View excerpts from successfully funded research grant applications to help prepare applications for NCI funding.

Sample Grant Applications

Funding Inquiry Staff Contact

Clinical Trials & Implementation Science

NIH Clinical Trial Policies

In 2016, NIH launched a multi-faceted effort to enhance its stewardship over clinical trials. The goal of this effort is to encourage advances in the design, conduct, and oversight of clinical trials while elevating the entire biomedical research enterprise to a new level of transparency and accountability. The NIH definition of a clinical trial was revised in 2014 in anticipation of these stewardship reforms to ensure a clear and responsive definition of a clinical trial. If you need assistance determining whether your proposed study is a clinical trial, visit the NIH Office of Extramural Research (OER) clinical trial website.

What is a Clinical Trial?

The NIH definition of a clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.

Clinical Trial-Specific Funding Opportunities

NIH requires that all applications involving one or more clinical trials be submitted through a Funding Opportunity Announcement (FOA) specifically designed for clinical trials. The purpose of this policy is to improve our ability to identify proposed clinical trials, ensure that key pieces of trial-specific information are submitted with each application, and uniformly apply trial-specific review criteria. FOAs are classified as Clinical Trial Optional, Clinical Trial Required, or Clinical Trial Not Allowed.

More Prospective Grantee Resources

NCI’s Dr. David Chambers and representatives from other institutes and centers discuss the 2019 Trans-NIH Funding Announcement for Dissemination and Implementation Research in Health (DIRH).

Webinar

DIRH Study Section reviews applications that focus on the dissemination and implementation of knowledge from scientific discovery to transform health care delivery, improve health outcomes, and manage acute and chronic illness. Studies focus on how health information, interventions and scientifically based clinical practices are adopted in public health and health care service use in a variety of settings.

Membership and Meeting Rosters

In 2015, IS team members published a portfolio analysis of dissemination and implementation grants funded by the NCI in cancer prevention and control between 2000 to 2012. The portfolio analysis identified 67 NCI grant awards with an implementation science focus. The R01 mechanism was the most common funding mechanism. Prevention grants were most common (49.3%) and cancer treatment grants were least (4.5%), with most grants including both quantitative and qualitative methods (69%).

Open-Access Article

Current and previous grants funded through the DIRH FOA in cancer prevention and control by DCCPS are listed in a searchable table for reference.

Funded Grants
Last Updated
September 24, 2020